secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-07-24T21:00:37+00:00
Accession:  0001493152-26-034601
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

BTIG terminates $50M at-the-market sales agreement with Matinas BioPharma
-------------------------------------------------------------------------

- BTIG terminated the ATM sales agreement effective July 23, 2026, under Section 12(a).
- The agreement allowed Matinas to sell up to $50M of common stock through BTIG.
- No termination penalties or expenses incurred by the company.
- Matinas loses access to this equity financing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/0001493152-26-034601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer